After disappointing results in other indications, AnaptysBio has a route to market with its IL-36 receptor inhibitor imsidolimab in a rare and life-threatening form of the
Boehringer Ingelheim and Zealand Pharma have kicked off three phase 3 trials of obesity drug candidate survodutide, in patients with and without diabetes, in the hope of b
An alliance between German pharma group Boehringer Ingelheim and an NHS trust in the UK has been launched with the aim of reducing recurring heart attacks in people with d
Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year.
Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with l
While at Reuters Pharma Europe in Barcelona the other week, pharmaphorum web editor Nicole Raleigh spoke with Florian Schnappauf, VP of enterprise commercial strategy at Veeva Europe, about
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.